Roche Holding AG - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RHHBY Over the counter 2834 www.roche.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Roche Holding AG

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - Aug 6th, 2026 2:05 pm
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - Aug 6th, 2026 12:05 pm
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View - Aug 6th, 2026 9:40 am
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down - Aug 6th, 2026 8:58 am
Roche Expands Cyclospora Testing Portfolio to Support U.S. Public Health Response - Aug 6th, 2026 8:53 am
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight - Aug 6th, 2026 8:31 am
Roche (SWX:ROP) Starts Breast Cancer Trial With Evexta Bio Using Two Drug Candidates - Aug 5th, 2026 4:14 pm
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins - Aug 5th, 2026 3:17 pm
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Aug 5th, 2026 2:12 pm
A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype - Aug 5th, 2026 6:00 am
Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant - Aug 5th, 2026 3:30 am
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer - Aug 4th, 2026 5:00 am
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 4th, 2026 4:00 am
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer - Aug 4th, 2026 1:00 am
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - Aug 3rd, 2026 11:00 pm
PTC Therapeutics Q2 Earnings Call Highlights - Jul 31st, 2026 7:02 pm
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down - Jul 31st, 2026 11:11 am
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut - Jul 31st, 2026 9:25 am
PTC Therapeutics Inc (PTCT) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... - Jul 30th, 2026 11:04 pm
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength - Jul 30th, 2026 9:58 am